Linked Life Data

10506726

Source:http://linkedlifedata.com/resource/pubmed/id/10506726

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
1999-10-18
pubmed:abstractText
Anemia has been reported to develop during preoperative chemotherapy with paclitaxel and carboplatin. The use of recombinant human erythropoietin (EPO) has been shown to reduce anemia and subsequent packed red blood cell transfusions. The current study is a report of a Phase III, prospective, randomized trial with or without EPO that confirms the original observations of less anemia and fewer transfusions in those patients randomized to receive EPO concurrently with paclitaxel and carboplatin.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0008-543X
pubmed:author
pubmed:copyrightInfo
Copyright 1999 American Cancer Society.
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
86
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1362-7
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1999
pubmed:articleTitle
Erythropoietin reduces anemia and transfusions: A randomized trial with or without erythropoietin during chemotherapy.
pubmed:affiliation
Division of Hematology and Oncology, Department of Internal Medicine, Saint Louis University Health Sciences Center, St. Louis, Missouri 63110-0250, USA.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Clinical Trial, Phase III